Oligonucleotide
Short synthetic strand of DNA or RNA used in genetic-disease treatments and as a production aid for RNA-based drugs and vaccines.
As defined in Agilent: Back To The Lab
Where it comes up · 1
- Agilent: Back To The Lab3 claims
Most important claims · 3 of 3Search all claims for “Oligonucleotide” →
- Agilent's Nucleic Acid Solutions Department (NADS) makes oligonucleotides used to stabilize RNA during production of RNA-based drugs and vaccines, including COVID-19 vaccines; it began as a tiny unit formed in 2006 from in-house RNA synthesis know-how and the SynPro acquisition, and it became the clear leader in the niche.Agilent: Back To The Lab
- Agilent has no competitor with equal or larger capacity for producing specialist oligonucleotides at production grade, so small quantities are easy to make but commercial volumes for vaccines and drugs effectively only Agilent can supply, and it works with all the main manufacturers of these drugs.Agilent: Back To The Lab
- NADS partners with drug developers early in development, customizing oligonucleotides while earning little money, with the payback arriving if the drug reaches commercialization and volume ramps.Agilent: Back To The Lab